ALZN (Alzamend Neuro) Total Equity: $0.73 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALZN Alzamend Neuro Inc ALZN
21 GF Score
Price $1.33
! 1 Warning Sign
View Full Analysis

What is Alzamend Neuro Total Equity?

Alzamend Neuro ALZN +0.75% 21 Total Equity is $0.73 Mil as of Apr. 2026. GuruFocus rates ALZN with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

Alzamend Neuro's total equity for the quarter that ended in Apr. 2026 was $0.73 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Alzamend Neuro Total Equity Historical Data

* Premium members only.

The historical data trend for Alzamend Neuro's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzamend Neuro Total Equity Chart

Alzamend Neuro Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Total Equity
Get a 7-Day Free Trial 13.35 3.05 -2.59 3.97 0.73

Alzamend Neuro Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.97 5.34 4.37 2.19 0.73
ALZN
21GF Score
Alzamend Neuro Inc ALZN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzamend Neuro Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Alzamend Neuro's Total Equity for the fiscal year that ended in Apr. 2026 is calculated as

Total Equity=Total Assets(Q: Apr. 2026 )-Total Liabilities(Q: Apr. 2026 )
=2.079-1.346
=0.73

Alzamend Neuro's Total Equity for the quarter that ended in Apr. 2026 is calculated as

Total Equity=Total Assets(Q: Apr. 2026 )-Total Liabilities(Q: Apr. 2026 )
=2.079-1.346
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $0.73 Mil mean?
Alzamend Neuro (ALZN) has a Total Equity of $0.73 Mil as of Apr. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Alzamend Neuro and its competitors.
Is Alzamend Neuro's Total Equity too high?
Alzamend Neuro's current Total Equity is $0.73 Mil. Overall, Alzamend Neuro has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Alzamend Neuro's Total Equity compare to SILO and BGMS?
Alzamend Neuro's Total Equity of $0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Alzamend Neuro and its competitors. Alzamend Neuro's current Total Equity is $0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzamend Neuro stock overvalued right now?
Alzamend Neuro (ALZN) has a current Total Equity of $0.73 Mil. The current Total Equity is $0.73 Mil. Alzamend Neuro's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Alzamend Neuro (ALZN), the current Total Equity is $0.73 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzamend Neuro Business Description

Address 3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
21GF Score

Get the complete analysis for ALZN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.33
Price